Transgene is a clinical-stage biotechnology company headquartered in Strasbourg, France, dedicated to designing and developing targeted immunotherapies for cancer and infectious diseases. Founded in 1979, the company combines expertise in virology, gene engineering and immunology to create viral-based vectors that deliver therapeutic genes or antigens directly into patient tissues. In the United States, Transgene’s American Depositary Receipts trade under the symbol TRGNF.
The company’s proprietary platforms include an oncolytic vaccine technology that harnesses genetically modified viruses to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immunity. Lead oncology candidates include TG4001, an HPV-targeted immunotherapy being evaluated in combination regimens for HPV-associated malignancies, and TG4050, a personalized neoantigen vaccine tailored to each patient’s tumor antigen profile. In parallel, Transgene leverages a Modified Vaccinia Ankara (MVA) platform to develop prophylactic and therapeutic vaccines against emerging infectious agents.
Transgene advances its pipeline through strategic collaborations with global pharmaceutical partners and academic research centers. These alliances provide access to complementary clinical development resources, enabling accelerated evaluation of vaccine and immunotherapy candidates across multiple cancer types and viral targets. Collaborative programs also extend the company’s manufacturing capabilities for complex viral vectors, supporting seamless transition from research to late-stage clinical studies.
With clinical trial sites throughout Europe and North America, Transgene oversees Phase I and II studies in leading oncology and infectious disease centers. Its multidisciplinary management team and board of directors bring extensive experience in drug development, regulatory affairs and translational science. By integrating innovative vector design with precision immunotherapy approaches, Transgene aims to address high-unmet medical needs and improve patient outcomes in oncology and emerging infectious diseases around the world.
AI Generated. May Contain Errors.
Free TRGNF Stock Alerts